Zanthoxylum schinifolium has been used as culinary applications in Asia and some of its elements have been elucidated to have various pharmaceutical effects such as anti-platelet aggregation, inhibitory activities against monoamine oxidase, antioxidant and anticancer activities, and anti-inflammatory activity. In this study 21-day repeated Zanthoxylum schinifolium oral administration (250 mg/kg/day, once a day) modulated B cell-related immunity and biologically safe. After 21-day repeated oral administration, the expression of CD19 bound cells was significantly increased compared to those of the other surface molecules and the percentages of Alamar $Blue^{(R)}$ reduction were in LPS-treated splenocytes higher than in no treated but it was not different with in Con A-treated splenocytes and in no treated. Twenty-one-day repeated Z. schinifolium administration could not change the index of biological safety such as CBC, hematological enzymes, and especially histopathological morphologies. From the results Z. schinifolium-repeated administration enhances B cell immunity and is biological safe. Conclusively Z. schinifolium is one of the safe candidates to modulate immunity.